A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Erosive oesophagitis; Gastro-oesophageal reflux; Gastrointestinal disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 08 Feb 2018 Status changed from recruiting to completed.
- 22 Jan 2018 Planned End Date changed from 9 Jan 2018 to 30 Jan 2018.
- 22 Jan 2018 Planned primary completion date changed from 28 Dec 2017 to 26 Jan 2018.